thalidomide has been researched along with zd 6126 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Cona, MM; De Geest, B; De Keyzer, F; Feng, Y; Jiang, Y; Li, J; Marchal, G; Ni, Y; Oyen, R; Verfaillie, C; Wang, H; Yu, J; Zheng, K | 1 |
| Chen, F; Cona, MM; De Keyzer, F; Feng, YB; Marchal, G; Ni, YC; Oyen, R; Yu, J | 1 |
2 other study(ies) available for thalidomide and zd 6126
| Article | Year |
|---|---|
Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chemokine CXCL12; Endothelial Cells; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Microcirculation; Necrosis; Organophosphorus Compounds; Rats; Stem Cells; Thalidomide | 2012 |
Separate calculation of DW-MRI in assessing therapeutic effect in liver tumors in rats.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Diffusion Magnetic Resonance Imaging; Liver; Liver Neoplasms, Experimental; Necrosis; Organophosphorus Compounds; Predictive Value of Tests; Rats; Rhabdomyosarcoma; Thalidomide; Time Factors; Tumor Burden | 2013 |